Oppenheimer Asset Management Inc. bought a new position in shares of Avantor, Inc. (NYSE:AVTR – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 81,327 shares of the company’s stock, valued at approximately $805,000.
Several other large investors have also recently modified their holdings of AVTR. Handelsbanken Fonder AB lifted its stake in shares of Avantor by 41.2% during the 2nd quarter. Handelsbanken Fonder AB now owns 278,500 shares of the company’s stock valued at $2,757,000 after buying an additional 81,200 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Avantor by 425.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock valued at $5,513,000 after acquiring an additional 450,801 shares during the period. GAMMA Investing LLC lifted its position in shares of Avantor by 93.3% during the second quarter. GAMMA Investing LLC now owns 46,592 shares of the company’s stock worth $461,000 after acquiring an additional 22,491 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Avantor by 372.1% during the second quarter. Versant Capital Management Inc now owns 9,073 shares of the company’s stock worth $90,000 after acquiring an additional 7,151 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Avantor by 21.4% in the first quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock worth $66,000 after acquiring an additional 1,491 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Wall Street Analyst Weigh In
AVTR has been the topic of a number of analyst reports. UBS Group set a $8.00 price objective on Avantor in a research note on Wednesday, June 24th. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target on the stock in a research report on Wednesday, July 29th. Citigroup increased their price target on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Evercore set a $10.50 price objective on shares of Avantor in a research note on Monday, July 6th. Finally, Zacks Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Two analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Avantor has a consensus rating of “Hold” and an average price target of $12.00.
Avantor Price Performance
Avantor stock opened at $13.52 on Tuesday. The stock has a market cap of $9.14 billion, a price-to-earnings ratio of -16.10, a PEG ratio of 10.29 and a beta of 0.89. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The business has a 50-day simple moving average of $11.28 and a 200 day simple moving average of $9.55. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93.
Avantor (NYSE:AVTR – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter last year, the firm posted $0.24 EPS. The company’s revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, research analysts forecast that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.
About Avantor
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Read More
- Five stocks we like better than Avantor
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
